Refractive Status and Accommodation Response Under Different Experimental Conditions.

NCT ID: NCT06331780

Last Updated: 2024-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-22

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eye Care Professionals (ECPs) massively use auto-refractors during the patient journey to measure the objective refractive error: starting point of the subjective eye refraction. These devices provide objective information about the refractive and accommodative state of the eye, useful for the ECP to perform a complete eyesight test. Auto-refractor data for the distance vision are repeatable and accurate but near vision information are not enough reliable to build an accurate near vision routine exam. Previous internal studies, with auto refractors currently on the market, have shown that, during accommodation measurements, a large proportion of participants had a lower accommodative response than expected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical Development stage and rationale

The clinical development stage is pilot stage as defined in ISO 14155:2020 (Annex I section 1.3.2).This clinical investigation is an exploratory clinical investigation as mentioned in the Medical Device Regulation EU 745/2017, also named early feasibility clinical investigation in the ISO 14155:2020. The necessity of such clinical investigations is more precisely described by the Food and Drug Administration (FDA) (Attachment E CDRH Final Guidance Cover Sheet) and Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), where they detail the importance of exploratory studies in pivotal investigation design.

Medical devices often undergo design improvement during development, with refinement during lifecycles beginning with early research, extending through investigational use and initial marketing of the approved or cleared product, and continuing to subsequently approved or cleared commercial device versions.

Objectives and hypotheses of the clinical investigation

This clinical investigation explores new ways of measuring accommodative response, particularly regarding the dynamics and amplitude of response: we chose to vary several parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Accommodation Disorder Accommodative Fatigue Accommodative Inertia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Closed-field Aberrometer

Objective refraction at different distances with Shack-Hartmann Aberrometer

Group Type EXPERIMENTAL

Visual acuity

Intervention Type DEVICE

VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Objective refraction

Intervention Type DEVICE

Objective refraction will be measured using an auto-kerato-refractometer/aberrometer

Objective monocular accommodation amplitude measurement

Intervention Type DEVICE

Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance

Subjective monocular accommodation amplitude measurement with the "Push-Up" method

Intervention Type DEVICE

The subjective monocular accommodation amplitude measurements are carried out by the "push-up" method and proceeds as follows:

* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.
* Instructions to the subject: "Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.
* The ECP slowly brings the test card closer
* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.

The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived.

Subjective monocular accommodation facility measurement with the "Rock" method:

Intervention Type DEVICE

The subjective monocular accommodation facility measurements are carried out by the "Rock" method and proceeds as follows:

* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.
* The ECP gives to the participant a flipper +/- 2 Dioptre
* Instructions to the subject: "Look at the test" and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc… You have to do the maximum number of rotations in one minute.

CISS Questionnaire

Intervention Type OTHER

This questionnaire relating to the use of the near vision will be submitted

Difficulty assessment questionnaire

Intervention Type OTHER

After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.

Subjective evaluation questionnaire

Intervention Type OTHER

A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual acuity

VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Intervention Type DEVICE

Objective refraction

Objective refraction will be measured using an auto-kerato-refractometer/aberrometer

Intervention Type DEVICE

Objective monocular accommodation amplitude measurement

Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance

Intervention Type DEVICE

Subjective monocular accommodation amplitude measurement with the "Push-Up" method

The subjective monocular accommodation amplitude measurements are carried out by the "push-up" method and proceeds as follows:

* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.
* Instructions to the subject: "Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.
* The ECP slowly brings the test card closer
* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.

The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived.

Intervention Type DEVICE

Subjective monocular accommodation facility measurement with the "Rock" method:

The subjective monocular accommodation facility measurements are carried out by the "Rock" method and proceeds as follows:

* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.
* The ECP gives to the participant a flipper +/- 2 Dioptre
* Instructions to the subject: "Look at the test" and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc… You have to do the maximum number of rotations in one minute.

Intervention Type DEVICE

CISS Questionnaire

This questionnaire relating to the use of the near vision will be submitted

Intervention Type OTHER

Difficulty assessment questionnaire

After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.

Intervention Type OTHER

Subjective evaluation questionnaire

A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteer: man or woman from 18 to 40 years old,
* Subject declares that his last visit to an ophthalmologist was less than 12 months ago,
* Subjects without a reported pathology, deficit or disorder that can interfere with visual or cognitive functions,
* Subjects, healthy volunteers who have been fully informed of the investigation and signed the informed consent form of the investigation,
* Subjects available for the investigation visits (at least 2 hours),
* Subjects able to appoint a visit in the investigator's site,
* Subjects able to read and understand the protocol (in French), follow the instructions, and give their informed consent approval.

Exclusion Criteria

* Subjects with spherical equivalent wearing compensation (or fully compensate by contact lenses) ranging out from -3.00 to + 3.00 Dioptres in both eyes,
* Subjects with an astigmatism wearing compensation (or fully compensate by contact lenses) more than 1.00 Dioptres (\>1,00DC) in both eyes,
* Subjects with a best compensated monocular VA \< 8/10 (\>0.1logMAR),
* Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice, etc.) or unable to express their consent (see Article L 1121-8 of the CSP)
* Persons deprived of their liberty by judicial or administrative decision and persons hospitalised without their consent (article L1121-6 of the CSP),
* Subjects under exclusion period from another investigation,
* Women pregnant or breastfeeding; (Article L1121-5),
* Subjects with a reported neurologic disorder, particularly epileptic or sensory motor troubles,
* Subjects with implanted electronic medical device such as (pacemaker or hearing aid),
* Subjects with a reported severe ocular disease leading to a visual field decrease, VA deficiency or glare sensitivity,
* Subjects with monophtalmia
* Subjects who had ocular surgeries (including aphakia or pseudophakia (intraocular lenses), refractive surgery or trauma),
* Subjects who are ESSILOR INTERNATIONAL employees
* Subjects who are not affiliated to a social security scheme or are beneficiaries of such a scheme (article L1121-8-1 of the CSP).
* Subject with fixation disorder: impossibility to maintain fixation on visual target.
* Subjects who cannot stay comfortable during the tests (e.g. with neck pain ...).
* Pupil abnormality (unusual shape, size \<3mm)
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Essilor International

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jérôme Gillet

Role: PRINCIPAL_INVESTIGATOR

ESSILOR INTERNATIONAL - Division Instruments

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Essilor International - Ci&T 2

Créteil, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thierry Laloux

Role: CONTACT

+33 (1) 55 96 54 05

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jérôme Gillet

Role: primary

+33 (0)1 49 80 63 40

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A02153-42

Identifier Type: OTHER

Identifier Source: secondary_id

WS10370

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.